
    
      In this double blind, placebo-controlled, crossover study, 20 asthmatics and 20 COPD patients
      received ivabradine 7,5 mg b.i.d. and placebo for 5 days in crossover manner. HR in ECG
      holter monitoring, peak expiratory flow rate (PEFR), symptoms, rescue medication consumption
      and AEs were evaluated in both periods of treatment.
    
  